ArticleInternational journal of molecular sciences2026

PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway.

Shan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.